- Trials with a EudraCT protocol (75)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1)
75 result(s) found for: DNA polymerase.
Displaying page 1 of 4.
EudraCT Number: 2004-000501-21 | Sponsor Protocol Number: 2003-12 | Start Date*: 2005-04-30 |
Sponsor Name:XTL Biopharmaceuticals | ||
Full Title: A Phase II, Multicenter, Randomized, Open-Label, Dose-Ranging, Parallel Group Study to Compare the Anti-Viral Effects, Pharmacokinetics and Safety of HepeX-B, a Mixture of Two Monoclonal Antibodies... | ||
Medical condition: Hepatic allograft recipients for treatment of hepatitis B virus infection. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-002458-66 | Sponsor Protocol Number: AI443-113 | Start Date*: 2013-12-13 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Phase 3 Evaluation of a daclatasvir/asunaprevir/BMS-791325 Fixed Dose Combination in Subjects with Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis | |||||||||||||
Medical condition: HEPATITIS C VIRUS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001457-50 | Sponsor Protocol Number: SIL-TH-01 | Start Date*: 2012-05-23 |
Sponsor Name:fUNDACIÓN iNVESTIGACIÓN HOSPITAL RAMÓN Y CAJAL | ||
Full Title: Study on the effect of intravenous silimaryn in the perioperative period of liver transplantation (before, during and after) for the prevention and prognosis of hepatitis C virus reinfection of the... | ||
Medical condition: Patients transplanted for chronic liver disease or hepatocarcinoma relating to C virus being replicated at the time of the OLT (orthotopic liver transplantation). | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2008-006239-11 | Sponsor Protocol Number: HBV 09-01 | Start Date*: 2009-05-15 | |||||||||||
Sponsor Name:Stichting Lever Onderzoek | |||||||||||||
Full Title: Augmenting response to entecavir using a temporary peginterferon alpha-2a add-on strategy for the treatment of HBeAg-positive chronic hepatitis B (ARES study) | |||||||||||||
Medical condition: Chronic hepatitis B virus infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-003136-22 | Sponsor Protocol Number: GS-US-174-0106 | Start Date*: 2006-05-05 | |||||||||||
Sponsor Name:Gilead Sciences Incorporated | |||||||||||||
Full Title: A Phase 2, Randomized, Double-Blind Study Exploring the Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate (DF) Monotherapy Versus Emtricitabine plus Tenofovir DF Fixed-Dose Combina... | |||||||||||||
Medical condition: Chronic Hepatitis B | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-000733-21 | Sponsor Protocol Number: ANRS HB 05 | Start Date*: 2008-10-10 | |||||||||||
Sponsor Name:ANRS | |||||||||||||
Full Title: A randomized, double blind, multicenter study evaluating efficacy and safety of Clevudine monotherapy versus Tenofovir monotherapy versus combination therapy of Clevudine and Tenofovir for 96 weeks... | |||||||||||||
Medical condition: For chronic HBV infection, an optimal pharmacological agent to promote recovery from chronic HBV infection would be one that inhibits HBV DNA polymerase, combined with the clearance from the liver... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-003953-34 | Sponsor Protocol Number: 101-001 | Start Date*: 2009-12-14 |
Sponsor Name:D2 Derma Europe Ltd. | ||
Full Title: A randomized, placebo-controlled, active comparator, observer-blinded multicentre phase II trial to evaluate the efficacy and safety of D2D001 in the treatment of HSV type 1 infection in the region... | ||
Medical condition: Herpes simplex virus type 1 infection in the region of the mouth and the openings of the nose | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2015-002931-16 | Sponsor Protocol Number: V501-122 | Start Date*: 2018-02-09 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase III Placebo-controlled Clinical Trial to Study the Tolerability, Immunogenicity and Efficacy of V501 in 16- to 26-year-old Japanese men | |||||||||||||
Medical condition: vaccination against HPV infection/related disease | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004360-10 | Sponsor Protocol Number: ALN-HBV-001 | Start Date*: 2016-04-06 | |||||||||||
Sponsor Name:Alnylam Pharmaceuticals, Inc | |||||||||||||
Full Title: A Phase 1/2, Randomized, Single-Blind, Placebo-Controlled, Single-Ascending and Multiple-Ascending Dose, Safety, Tolerability, Pharmacokinetics, and Antiviral Efficacy Study of Subcutaneously Admin... | |||||||||||||
Medical condition: Chronic Hepatitis B virus (HBV) Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004726-34 | Sponsor Protocol Number: SHP620-302 | Start Date*: 2017-09-01 | |||||||||||
Sponsor Name:Takeda Development Center Americas, Inc. | |||||||||||||
Full Title: A Phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled study to assess the efficacy and safety of maribavir compared to valganciclovir for the treatment of cytomegaloviru... | |||||||||||||
Medical condition: Cytomegalovirus Infection in Hematopoietic Stem Cell Transplant Recipients | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) DE (Completed) GB (GB - no longer in EU/EEA) ES (Completed) BE (Completed) CZ (Completed) PL (Completed) FR (Completed) HR (Completed) IT (Completed) GR (Completed) AT (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000586-20 | Sponsor Protocol Number: GS-US-174-0144 | Start Date*: 2013-01-23 | |||||||||||
Sponsor Name:Gilead Sciences Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind Evaluation of the Antiviral Efficacy, Safety, and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Patients with Chronic Hepatitis B Infection | |||||||||||||
Medical condition: Chronic Hepatitis B | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Prematurely Ended) BG (Prematurely Ended) Outside EU/EEA RO (Trial now transitioned) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-008258-21 | Sponsor Protocol Number: NV20536 eu | Start Date*: 2009-03-30 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A Randomized, Double-blinded, Multicenter, Dose and Duration Finding Study to Evaluate the Sustained Virologic Response of the HCV Polymerase Inhibitor Prodrug (RO5024048) in Combination with Pegas... | |||||||||||||
Medical condition: Chronic Hepatitis C | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) DE (Completed) ES (Completed) FR (Completed) GB (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003462-40 | Sponsor Protocol Number: 18IC07 | Start Date*: 2020-03-30 |
Sponsor Name:Great Ormond Street Hospital for Children NHS Trust | ||
Full Title: Phase 1 , open label study of CRISPR-CAR genome edited T cells (TT52CAR19) in relapsed /refractory B Cell Acute Lymphoblastic Leukaemia | ||
Medical condition: Relapsed/ refractory B- cell acute lymphoid leukaemia | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2013-002468-20 | Sponsor Protocol Number: AI443-102 | Start Date*: 2013-12-13 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Phase 3 Evaluation of a daclatasvir/asunaprevir/BMS-791325 Fixed Dose Combination in Non-cirrhotic Subjects with Genotype 1 Chronic Hepatitis C | |||||||||||||
Medical condition: HEPATITIS C VIRUS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003984-37 | Sponsor Protocol Number: CMX001-211 | Start Date*: 2018-07-30 | |||||||||||
Sponsor Name:Chimerix, Inc | |||||||||||||
Full Title: A Randomized, Controlled, Open-Label, Multiple Ascending Dose Study of Intravenous Brincidofovir in Adult Allogeneic Hematopoietic Cell Transplant Recipients with Adenovirus Viremia | |||||||||||||
Medical condition: Treatment of adenovirus infections in adult allogeneic hematopoietic cell transplant recipients | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-000896-17 | Sponsor Protocol Number: SBP-9200-HBV-206 | Start Date*: 2019-05-20 |
Sponsor Name:Spring Bank Pharmaceuticals, Inc. | ||
Full Title: A PHASE 2, EXPLORATORY STUDY EVALUATING THE SAFETY AND ANTIVIRAL EFFICACY OF INARIGIVIR SOPROXIL IN NON-CIRRHOTIC, HEPATITIS B e ANTIGEN NEGATIVE SUBJECTS INFECTED WITH CHRONIC HEPATITIS B VIRUS AN... | ||
Medical condition: Chronic HBV-infected, HBeAg-negative subjects, who are non-cirrhotic and meet the cohort-specific criteria. Criteria for the planned cohorts are as follows: Cohort 1 Subjects who have been on NUC t... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-004274-87 | Sponsor Protocol Number: NV-02B-022 / CLDT600A2303 | Start Date*: 2005-09-30 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: An Open Label Trial of Telbivudine (LdT) in Adults with Chronic Hepatitis B Previously Treated in Idenix-Sponsored Telbivudine Studies | |||||||||||||
Medical condition: chronic hepatitis B | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) ES (Completed) CZ (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003450-22 | Sponsor Protocol Number: P-105-303 | Start Date*: 2022-03-08 | |||||||||||
Sponsor Name:AlloVir, Inc. | |||||||||||||
Full Title: Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial, with Cross-Over, of Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standar... | |||||||||||||
Medical condition: AdV infection in pediatric and adult allo HCT recipients receiving standard of care | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) IT (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003358-25 | Sponsor Protocol Number: PC10VAC02 | Start Date*: 2013-11-25 | |||||||||||
Sponsor Name:Genticel | |||||||||||||
Full Title: A double-blind, randomised, placebo-controlled, Phase II study to evaluate ProCervix efficacy to clear HPV 16 and HPV 18 infection in women with normal cytology or ASCUS/LSIL | |||||||||||||
Medical condition: Women infected by HPV 16 and/or HPV 18 with normal cytology or ASCUS/LSIL | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: BE (Completed) GB (Completed) FI (Completed) DE (Completed) NL (Ongoing) ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001629-28 | Sponsor Protocol Number: EYP001-201 | Start Date*: 2019-11-06 | |||||||||||
Sponsor Name:ENYO Pharma SA | |||||||||||||
Full Title: A Phase 2a, randomized, double-blind, placebo-controlled study of oral FXR modulator EYP001a combined with nucleos(t)ide analogues (NA) in virologically suppressed chronic hepatitis B patients to i... | |||||||||||||
Medical condition: Chronic Hepatitis B | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Ongoing) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
